Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant adenovirus type 5 injection combined with tislelizumab and HAIC for advanced hepatocellular carcinoma
ChiCTR2300071481Phase 4Recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Oncorine, tislelizumab and durvalumab + lenvatinib + gemcitabine + cisplatin in hepatocellular carcinoma (HCC), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: Objective response rate. Started Aug 2022; status: recruiting.
02
Drugs
Oncorinetislelizumabdurvalumab + lenvatinib + gemcitabine + cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300071481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071481.